FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376454009> ?p ?o ?g. }

• W4376454009 endingPage "39" @default.
• W4376454009 startingPage "29" @default.
• W4376454009 abstract "OBJECTIVE To conduct a systematic review and meta-analysis of randomized trials that assessed the effect of testosterone use on cardiovascular events and risk factors in men with different degrees of androgen deficiency. METHODS Librarian-designed search strategies were used to search the MEDLINE (1966 to October 2004), EMBASE (1988 to October 2004), and Cochrane CENTRAL (inception to October 2004) databases. The database search was performed again in March 2005. We also reviewed reference lists from included studies and content expert files. Eligible studies were randomized trials that compared any formulation of commercially available testosterone with placebo and that assessed cardiovascular risk factors (lipid fractions, blood pressure, blood glucose), cardiovascular events (cardiovascular death, nonfatal myocardial infarction, angina or claudication, revascularization, stroke), and cardiovascular surrogate end points (ie, laboratory tests indicative of cardiac or vascular disease). Using a standardized data extraction form, we collected data on participants, testosterone administration, and outcome measures. We assessed study quality with attention to allocation concealment, blinding, and loss to follow-up. RESULTS The 30 trials included 1642 men, 808 of whom were treated with testosterone. Overall, the trials had limited reporting of methodological features that prevent biased results (only 6 trials reported allocation concealment), enrolled few patients, and were of brief duration (only 4 trials followed up patients for >1 year). The median loss to follow-up across all 30 trials was 9%. Testosterone use in men with low testosterone levels led to inconsequential changes in blood pressure and glycemia and in all lipid fractions (total cholesterol: odds ratio [OR], -0.22; 95% confidence interval [CI], -0.71 to 0.27; high-density lipoprotein cholesterol: OR, -0.04; 95% CI, -0.39 to 0.30; low-density lipoprotein cholesterol: OR, 0.06; 95% CI, -0.30 to 0.42; and triglycerides: OR, -0.27; 95% CI, -0.61 to 0.08); results were similar in patients with low-normal to normal testosterone levels. The OR between testosterone use and any cardiovascular event pooled across trials that reported these events (n=6) was 1.82 (95% CI, 0.78 to 4.23). Several trials failed to report data on measured outcomes. For reasons we could not explain statistically, the results were inconsistent across trials. CONCLUSION Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects. Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use. To conduct a systematic review and meta-analysis of randomized trials that assessed the effect of testosterone use on cardiovascular events and risk factors in men with different degrees of androgen deficiency. Librarian-designed search strategies were used to search the MEDLINE (1966 to October 2004), EMBASE (1988 to October 2004), and Cochrane CENTRAL (inception to October 2004) databases. The database search was performed again in March 2005. We also reviewed reference lists from included studies and content expert files. Eligible studies were randomized trials that compared any formulation of commercially available testosterone with placebo and that assessed cardiovascular risk factors (lipid fractions, blood pressure, blood glucose), cardiovascular events (cardiovascular death, nonfatal myocardial infarction, angina or claudication, revascularization, stroke), and cardiovascular surrogate end points (ie, laboratory tests indicative of cardiac or vascular disease). Using a standardized data extraction form, we collected data on participants, testosterone administration, and outcome measures. We assessed study quality with attention to allocation concealment, blinding, and loss to follow-up. The 30 trials included 1642 men, 808 of whom were treated with testosterone. Overall, the trials had limited reporting of methodological features that prevent biased results (only 6 trials reported allocation concealment), enrolled few patients, and were of brief duration (only 4 trials followed up patients for >1 year). The median loss to follow-up across all 30 trials was 9%. Testosterone use in men with low testosterone levels led to inconsequential changes in blood pressure and glycemia and in all lipid fractions (total cholesterol: odds ratio [OR], -0.22; 95% confidence interval [CI], -0.71 to 0.27; high-density lipoprotein cholesterol: OR, -0.04; 95% CI, -0.39 to 0.30; low-density lipoprotein cholesterol: OR, 0.06; 95% CI, -0.30 to 0.42; and triglycerides: OR, -0.27; 95% CI, -0.61 to 0.08); results were similar in patients with low-normal to normal testosterone levels. The OR between testosterone use and any cardiovascular event pooled across trials that reported these events (n=6) was 1.82 (95% CI, 0.78 to 4.23). Several trials failed to report data on measured outcomes. For reasons we could not explain statistically, the results were inconsistent across trials. Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects. Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use." @default.
• W4376454009 created "2023-05-14" @default.
• W4376454009 creator A5013803607 @default.
• W4376454009 creator A5022482688 @default.
• W4376454009 creator A5026058045 @default.
• W4376454009 creator A5036488282 @default.
• W4376454009 creator A5039838372 @default.
• W4376454009 creator A5051516231 @default.
• W4376454009 creator A5061691563 @default.
• W4376454009 creator A5064101584 @default.
• W4376454009 creator A5077257832 @default.
• W4376454009 date "2007-01-01" @default.
• W4376454009 modified "2023-10-17" @default.
• W4376454009 title "Testosterone and Cardiovascular Risk in Men: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials" @default.
• W4376454009 cites W1600041372 @default.
• W4376454009 cites W187530708 @default.
• W4376454009 cites W1969632703 @default.
• W4376454009 cites W1973233466 @default.
• W4376454009 cites W1976290551 @default.
• W4376454009 cites W1985364719 @default.
• W4376454009 cites W1994273184 @default.
• W4376454009 cites W2000442546 @default.
• W4376454009 cites W2007725108 @default.
• W4376454009 cites W2011113929 @default.
• W4376454009 cites W2033856747 @default.
• W4376454009 cites W2042003977 @default.
• W4376454009 cites W2043724130 @default.
• W4376454009 cites W2066946777 @default.
• W4376454009 cites W2067470987 @default.
• W4376454009 cites W2070789954 @default.
• W4376454009 cites W2071362018 @default.
• W4376454009 cites W2075118988 @default.
• W4376454009 cites W2096487978 @default.
• W4376454009 cites W2109964083 @default.
• W4376454009 cites W2110875178 @default.
• W4376454009 cites W2116827517 @default.
• W4376454009 cites W2123261150 @default.
• W4376454009 cites W2129631167 @default.
• W4376454009 cites W2131882149 @default.
• W4376454009 cites W2133251189 @default.
• W4376454009 cites W2134459289 @default.
• W4376454009 cites W2136743230 @default.
• W4376454009 cites W2136924707 @default.
• W4376454009 cites W2148126950 @default.
• W4376454009 cites W2149217977 @default.
• W4376454009 cites W2150101787 @default.
• W4376454009 cites W2159875592 @default.
• W4376454009 cites W2160753800 @default.
• W4376454009 cites W2166611782 @default.
• W4376454009 cites W2170952317 @default.
• W4376454009 cites W3036378166 @default.
• W4376454009 cites W4232635137 @default.
• W4376454009 cites W4234671649 @default.
• W4376454009 cites W4236787052 @default.
• W4376454009 cites W4251071461 @default.
• W4376454009 doi "https://doi.org/10.1016/s0025-6196(11)60964-6" @default.
• W4376454009 hasPublicationYear "2007" @default.
• W4376454009 type Work @default.
• W4376454009 citedByCount "165" @default.
• W4376454009 countsByYear W43764540092012 @default.
• W4376454009 countsByYear W43764540092013 @default.
• W4376454009 countsByYear W43764540092014 @default.
• W4376454009 countsByYear W43764540092015 @default.
• W4376454009 countsByYear W43764540092016 @default.
• W4376454009 countsByYear W43764540092017 @default.
• W4376454009 countsByYear W43764540092018 @default.
• W4376454009 countsByYear W43764540092019 @default.
• W4376454009 countsByYear W43764540092020 @default.
• W4376454009 countsByYear W43764540092021 @default.
• W4376454009 countsByYear W43764540092022 @default.
• W4376454009 countsByYear W43764540092023 @default.
• W4376454009 crossrefType "journal-article" @default.
• W4376454009 hasAuthorship W4376454009A5013803607 @default.
• W4376454009 hasAuthorship W4376454009A5022482688 @default.
• W4376454009 hasAuthorship W4376454009A5026058045 @default.
• W4376454009 hasAuthorship W4376454009A5036488282 @default.
• W4376454009 hasAuthorship W4376454009A5039838372 @default.
• W4376454009 hasAuthorship W4376454009A5051516231 @default.
• W4376454009 hasAuthorship W4376454009A5061691563 @default.
• W4376454009 hasAuthorship W4376454009A5064101584 @default.
• W4376454009 hasAuthorship W4376454009A5077257832 @default.
• W4376454009 hasConcept C126322002 @default.
• W4376454009 hasConcept C127413603 @default.
• W4376454009 hasConcept C142724271 @default.
• W4376454009 hasConcept C168563851 @default.
• W4376454009 hasConcept C204787440 @default.
• W4376454009 hasConcept C27081682 @default.
• W4376454009 hasConcept C2778425758 @default.
• W4376454009 hasConcept C2779279991 @default.
• W4376454009 hasConcept C2780645631 @default.
• W4376454009 hasConcept C500558357 @default.
• W4376454009 hasConcept C71924100 @default.
• W4376454009 hasConcept C78519656 @default.
• W4376454009 hasConcept C84393581 @default.
• W4376454009 hasConceptScore W4376454009C126322002 @default.
• W4376454009 hasConceptScore W4376454009C127413603 @default.
• W4376454009 hasConceptScore W4376454009C142724271 @default.
• W4376454009 hasConceptScore W4376454009C168563851 @default.

• next